Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. Early clinical studies have shown that the company’s lead asset, TTI-101, is well-tolerated and has clinical activity across a broad range of tumors. To learn more, visit www.tvardi.com.